Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2072 studies found for:    "Arthritis, Rheumatoid"
Show Display Options
Rank Status Study
21 Completed A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K;   Drug: Placebo
22 Completed The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
Condition: Arthritis, Rheumatoid
Intervention: Drug: infliximab
23 Completed A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K;   Drug: Placebo
24 Recruiting A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K
Condition: Arthritis, Rheumatoid
Intervention: Drug: ASP015K
25 Completed
Has Results
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: Etanercept;   Drug: Methotrexate
26 Completed The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: rosiglitazone XR
27 Completed A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: GW856553
28 Completed A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
Condition: Arthritis, Rheumatoid
Intervention: Drug: ASP015K
29 Completed A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K;   Drug: Placebo
30 Completed A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
Condition: Arthritis, Rheumatoid
Interventions: Drug: JNJ-40346527;   Drug: Placebo
31 Completed A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Sirukumab
32 Recruiting Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Biological: Golimumab Intravenous (IV);   Biological: Infliximab
33 Terminated Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: Otelixizumab;   Drug: Matching placebo
34 Recruiting The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment
Condition: Arthritis, Rheumatoid
Interventions: Drug: Tacrolimus;   Drug: MTX
35 Withdrawn A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients
Condition: Arthritis, Rheumatoid
Interventions: Drug: GSK706769;   Drug: Placebo
36 Completed
Has Results
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Biological: Golimumab 50 mg;   Biological: Golimumab 100 mg
37 Recruiting Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: GSK3196165;   Drug: MTX;   Drug: Folic acid;   Drug: Placebo
38 Not yet recruiting ART-I02 in Patients With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Genetic: ART-I02
39 Completed
Has Results
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
Condition: Arthritis, Rheumatoid
Interventions: Drug: Sirukumab 100 mg;   Drug: Sirukumab 50 mg;   Drug: Placebo
40 Active, not recruiting A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Sirukumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.